The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Future Oncology

• Publication date

  2011-04-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon.11.25PMID 21463141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

  2011cited by this paper
• Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.

  2011cited by this paper
• Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.

  2011cited by this paper
• KRAS and BRAF: drug targets and predictive biomarkers

  2011cited by this paper
• Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

  2010cited by this paper
• Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer

  2010cited by this paper
• Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

  2010cited by this paper
• Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.

  2010cited by this paper
• A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer

  2010cited by this paper
• EGFR mutations in non-small-cell lung cancer.

  2010cited by this paper
• Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

  2010cited by this paper
• Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer

  2010cited by this paper
• Understanding resistance to EGFR inhibitors—impact on future treatment strategies

  2010cited by this paper
• Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

  2010cited by this paper
• The molecular pathology of cancer

  2010cited by this paper
• Visualization of FISH Probes by dual-color chromogenic in situ hybridization.

  2010cited by this paper
• ALK, lung cancer, and personalized therapy: portent of the future?

  2010cited by this paper
• The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer

  2010cited by this paper
• Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

  2010cited by this paper
• Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

  2010cited by this paper
• Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

  2010cited by this paper
• KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

  2010cited by this paper
• BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer

  2010cited by this paper
• Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

  2009cited by this paper
• Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

  2009cited by this paper
• Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

  2009cited by this paper
• Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.

  2009cited by this paper
• Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe.

  2009cited by this paper
• Anaplastic lymphoma kinase: signalling in development and disease

  2009cited by this paper
• Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2009cited by this paper
• Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2009cited by this paper
• KRAS mutations in non-small cell lung cancer.

  2009cited by this paper
• Evidence for common clonal origin of multifocal lung cancers.

  2009cited by this paper
• EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

  2009cited by this paper
• KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

  2009cited by this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cited by this paper
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

  2009cited by this paper
• More is less—combining targeted therapies in metastatic colorectal cancer

  2009cited by this paper
• Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation.

  2009cited by this paper
• Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

  2009cited by this paper
• Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer

  2009cited by this paper
• Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

  2009cited by this paper
• EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

  2009cited by this paper
• Are RAS mutations predictive markers of resistance to standard chemotherapy?

  2009cited by this paper
• Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

  2009cited by this paper
• Molecular Alterations at 9q33.1 and Polyploidy in Asbestos-Related Lung Cancer

  2009cited by this paper
• EML4-ALK: honing in on a new target in non-small-cell lung cancer.

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

  2009cited by this paper
• The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

  2009cited by this paper
• Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

  2008cited by this paper
• EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

  2008cited by this paper
• Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma.

  2008cited by this paper
• Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

  2008cited by this paper
• Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

  2008cited by this paper
• Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

  2008cited by this paper
• Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

  2008cited by this paper
• Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

  2008cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti–Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non–Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine

  2008cited by this paper
• EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

  2008cited by this paper
• Epidermal growth factor receptor immunohistochemistry

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

  2008cited by this paper
• The Histopathology of BRAF-V600E–mutated Lung Adenocarcinoma

  2008cited by this paper
• Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

  2008cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non–Small Cell Lung Cancer

  2008cited by this paper
• Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

  2008cited by this paper
• Structure and clinical relevance of the epidermal growth factor receptor in human cancer.

  2008cited by this paper
• The anaplastic lymphoma kinase in the pathogenesis of cancer

  2008cited by this paper
• Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

  2008cited by this paper
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

  2008cited by this paper
• A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.

  2007cited by this paper
• Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib

  2007cited by this paper
• Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

  2007cited by this paper
• EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• High-throughput oncogene mutation profiling in human cancer

  2007cited by this paper
• Abnormalities of epidermal growth factor receptor in lung squamous‐cell carcinomas, adenosquamous carcinomas, and large‐cell carcinomas

  2007cited by this paper
• Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

  2007cited by this paper
• EGFR mutations in small-cell lung cancers in patients who have never smoked.

  2006cited by this paper
• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

  2006cited by this paper
• Epidermal growth factor receptor (EGFR) signaling in cancer.

  2006cited by this paper
• Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

  2006cited by this paper

• Mitochondria-Targeted Molecular Tools in Precise Tumor Therapy.

  2025cites this paper
• Epigenetic code underlying EGFR-TKI resistance in non-small-cell lung cancer: elucidation of mechanisms and perspectives on therapeutic strategies.

  2025cites this paper
• Explainable 18F-FDG PET/CT radiomics model for predicting EGFR mutation status in lung adenocarcinoma: a two-center study

  2024cites this paper
• Development of a Supermolecular Radionuclide-Drug Conjugate System for Integrated Radiotheranostics for Non-small Cell Lung Cancer.

  2024cites this paper
• The Epidermal Growth Factor, Anaplastic Lymphoma Kinase, and ROS Proto-oncogene 1 Mutation Profile of Non-Small Cell Lung Carcinomas in the Turkish Population: A Single-Center Analysis

  2024cites this paper
• Value of multi-center 18 F-FDG PET/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma.

  2024cites this paper
• Development of a NIR fluorescent probe for fluorescence-assisted EGFR-TKI applicable patients screening and drug resistance monitoring.

  2023cites this paper
• Identification of EGFR-Related LINC00460/mir-338-3p/MCM4 Regulatory Axis as Diagnostic and Prognostic Biomarker of Lung Adenocarcinoma Based on Comprehensive Bioinformatics Analysis and Experimental Validation

  2022cites this paper
• Low expression of the metabolism-related gene SLC25A21 predicts unfavourable prognosis in patients with acute myeloid leukaemia

  2022cites this paper
• Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population with Non-small Cell Lung Cancer

  2021cites this paper
• Cell signaling pathways as molecular targets to eliminate AML stem cells.

  2021cites this paper
• Molecular mechanisms of anticancer effect of rutin

  2020cites this paper
• Retrospective study on the clinicogenomic characteristics of EGFR mutant and EGFR wildtype NSCLC

  2020cites this paper
• An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors

  2020influential citation
• Introduction and Application of Fine Needle Aspiration Biopsy

  2018cites this paper
• Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies

  2017cites this paper
• Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data.

  2017cites this paper
• Handbook of Practical Fine Needle Aspiration and Small Tissue Biopsies

  2017cites this paper
• Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.

  2017cites this paper
• Individualized Medicine in Ovarian Cancer: Are We There Yet?

  2017cites this paper
• Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

  2017cites this paper
• An overall review of targeted therapy in solid cancers

  2017cites this paper
• Targeted Therapy and Prevention of Endometrial Cancer

  2017cites this paper
• Silencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells.

  2016cites this paper
• Epidermal growth factor receptor and notch signaling in non‐small‐cell lung cancer

  2016cites this paper
• Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging.

  2016cites this paper
• Target Therapy in Lung Cancer.

  2016cites this paper
• Presence of PCR artifacts in Sanger sequencing in Formalin-fixed paraffin-embedded (FFPE) tissue – experience in a collective of 990 advanced NSCLC

  2016cites this paper
• Two-temperature formalin fixation preserves activation states efficiently.

  2015cites this paper
• Antitumor effect of miR-197 targeting in p53 wild-type lung cancer

  2014cites this paper
• EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder

  2014cites this paper
• EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study

  2014influential citation
• Rutin mediated targeting of signaling machinery in cancer cells

  2014cites this paper
• Utility of molecular tests in cytopathology

  2014cites this paper
• Biomarkers in bladder cancer: translational and clinical implications.

  2014cites this paper
• Targeted therapy sensitivity and resistance in solid malignancies

  2014cites this paper
• Epidermal growth factor‐induced cellular invasion requires sphingosine‐1‐phosphate/sphingosine‐1‐phosphate 2 receptor‐mediated ezrin activation

  2013cites this paper
• Epidermal growth factor receptor and Kras gene expression: Reliability of mutational analysis on cytological samples

  2013cites this paper
• EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

  2013cites this paper
• Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.

  2013cites this paper
• Clonality analysis and tumor of unknown primary: Applications in modern oncology and surgical pathology

  2013cites this paper
• Investigational agents in development for the treatment of ovarian cancer

  2013cites this paper
• Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

  2013cites this paper
• Personalized therapy in endometrial cancer: Challenges and opportunities

  2012cites this paper
• Current world literature.

  2012cites this paper
• Molecular Pathology of Bladder Cancer

  2012cites this paper
• Bladder Cancer: General Features

  2012cites this paper
• Tissue‐based Biomarkers

  2012cites this paper
• Digital pathology in personalized cancer therapy.

  2012cites this paper
• Digital pathology in personalized cancer therapy.

  2012cites this paper
• Personalized care in uterine cancer.

  2012cites this paper
• Molecular pathology of lung cancer: key to personalized medicine

  2012cites this paper
• Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways.

  2011cites this paper